Screening for Prostate Cancer: Results of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer
- 1 October 2013
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 64 (4), 530-539
- https://doi.org/10.1016/j.eururo.2013.05.030
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Prostate Cancer Mortality in the Finnish Randomized Screening TrialJNCI Journal of the National Cancer Institute, 2013
- Prostate-Cancer Mortality at 11 Years of Follow-upNew England Journal of Medicine, 2012
- Mortality results from the Göteborg randomised population-based prostate-cancer screening trialThe Lancet Oncology, 2010
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- PROSTATE CANCER DETECTION IN THE PROSTATE SPECIFIC ANTIGEN RANGE OF 2.0 TO 3.9 NG/ML: VALUE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN ON TUMOR DETECTION AND TUMOR AGGRESSIVENESSJournal of Urology, 2004
- Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM)Urology, 2004
- Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands)BJU International, 2003
- Quality assessment for prostate‐specific antigen (PSA) in relation to ERSPC: report of the PSA CommitteeBJU International, 2003
- Determining the cause of death in randomized screening trial(s) for prostate cancerBJU International, 2003
- Systematic 5 Region Prostate Biopsy is Superior to Sextant Method for Diagnosing Carcinoma of the ProstateJournal of Urology, 1997